

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7423347

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
METHYLATION SCIENCES INTERNATIONAL SRL	12/30/2019
RECEIVING PARTY DATA	
Name:	MSI METHYLATION SCIENCES INC.
Street Address:	15300 CROYDON DRIVE
Internal Address:	SUITE 300
City:	SURREY
State/Country:	CANADA
Postal Code:	V3Z 0Z5
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	8329208
Patent Number:	8580296
Patent Number:	8865203
Patent Number:	9931356
Patent Number:	8975238
Patent Number:	9801896
Patent Number:	9925208
Application Number:	15902877
Application Number:	15932359
CORRESPONDENCE DATA	
Fax Number:	(202)677-4945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202.677.4030
Email:	IP.Docketing@AGG.com
Correspondent Name:	ARNALL GOLDEN GREGORY LLP
Address Line 1:	1775 PENNSYLVANIA AVENUE NW
Address Line 2:	SUITE 1000
Address Line 4:	WASHINGTON, D.C. 20006
ATTORNEY DOCKET NUMBER:	37426.MSI

PATENT

NAME OF SUBMITTER:	BETH DONOVAN
SIGNATURE:	/Beth Donovan/
DATE SIGNED:	07/08/2022
Total Attachments: 7 source=MSI Methylation Assignment#page1.tif source=MSI Methylation Assignment#page2.tif source=MSI Methylation Assignment#page3.tif source=MSI Methylation Assignment#page4.tif source=MSI Methylation Assignment#page5.tif source=MSI Methylation Assignment#page6.tif source=MSI Methylation Assignment#page7.tif	

ASSIGNMENT OF INTELLECTUAL PROPERTY	Docket Number 34742-700
<p>WHEREAS, METHYLATION SCIENCES INTERNATIONAL SRL (hereinafter "Assignor"), owns the entire right, title and interest in and to certain, and/or all, of the inventions disclosed in the Application(s), and in and to certain, and/or all, embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") as set forth in Annex A hereto:</p> <p>WHEREAS, MSI METHYLATION SCIENCES INC., a corporation incorporated under the laws of Canada, having a place of business at 15300 Croydon Drive, Suite 300, Surrey, BC, CANADA V3Z 0Z5 (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, Canada, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").</p> <p>NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:</p> <ol style="list-style-type: none"> 1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee all of Assignor's right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s). 2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions. Should the Assignee be unable to secure the Assignor's signature on any document necessary to apply for, prosecute, obtain, enforce or assign any right herein, including but not limited to any patent, copyright or other right or protection relating to any Invention or Application, due to the Assignor's corporate dissolution or any other cause, the Assignor hereby irrevocably designates and appoints the Assignee and each of its duly authorized officers and agents as the Assignor's agent and attorney-in-fact to do all lawfully permitted acts to further the prosecution, issuance, enforcement and assignment of patents, copyrights, and all other rights granted herein or protection with the same force and effect as if executed and delivered by the Assignor. 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives. 4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith. 	

ASSIGNMENT OF INTELLECTUAL PROPERTY

Docket Number 34742-700

5. Said Assignor hereby request that any Patent(s) issuing in the United States, Canada, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the country of Canada, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

ASSIGNOR Methylation Sciences International SRLDate: Dec 30, 2019By: 

Name:

Title:

RECEIVED AND AGREED TO BY ASSIGNEE: MSI Methylation Sciences Inc.Date: Dec 30, 2019By: 

Name: David MacDonald

Title: President

ANNEX A

Application No.	Country	Patent No.	Filing Date	Issue Date	Title
60/887,565	US		1/31/2007		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
12/024,059	US		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
12/175,432	US		7/17/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
12/182,036	US		7/29/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
PCT/US2008/052726	WO		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
PCT/US2009/36703	WO		3/10/2009		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
PCT/US2009/51076	WO		7/17/2009		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
PCT/US2015/25606	WO		4/15/2015		Novel Ademetionine Formulations
2008210327	AU	2008210327	1/31/2008	9/29/2011	Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
2,677,053	CA	2,677,053	1/31/2008	3/15/2016	Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
200880010138.2	CN		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
8728778.5	EP		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
10109119.5	HK		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
4952/DELNP/2009	IN		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
2009-548461	JP		1/31/2008		Extended Release Pharmaceutical Formulations Of S-Adenosylmethionine
61/229,186	US		7/28/2009		Pharmacokinetics Of S-Adenosylmethionine Formulations
61/565,406	US		11/30/2011		S-Adenosylmethionine Formulations
12/845,600	US	8,329,208	7/28/2010	12/11/2012	Pharmacokinetics Of S-Adenosylmethionine Formulations
13/706,188	US	8,865,203	12/5/2012	6/13/2013	Pharmacokinetics Of S-Adenosylmethionine Formulations
13/714,246	US	8,580,296	12/13/2012	11/12/2013	Pharmacokinetics Of S-Adenosylmethionine Formulations
14/472,204	US		8/24/2014		Pharmacokinetics Of S-Adenosylmethionine Formulations
15/245,105	US	9,931,356	8/23/2016	12/15/2016	Pharmacokinetics Of S-Adenosylmethionine Formulations
15/902,877	US		2/22/2018		Pharmacokinetics Of S-Adenosylmethionine Formulations
PCT/IB2010/01879	WO		7/29/2010		Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
2010277302	AU	2010277302	7/29/2010	9/18/2014	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
2013204928	AU		7/29/2010		Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
2,769,490	CA	2,769,490	7/29/2010	4/1/2014	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	CH	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations

Application No.	Country	Patent No.	Filing Date	Issue Date	Title
201080044719.5	CN		7/29/2010		Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	DE	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	EP	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	FR	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	GB	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
12107972.3	HK	1167317B	7/29/2010	11/20/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	IE	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
1572/DELNP/2012	IN	288387	7/29/2010	10/13/2017	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	IT	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
2012-522273	JP		7/29/2010		Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10-2012-7005234	KR		7/29/2010		Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
10751713.8	NL	2464358	7/29/2010	7/17/2015	Improved Pharmacokinetics Of S-Adenosylmethionine Formulations
61/229,194	US		7/28/2009		S-Adenosylmethionine Formulations With Enhanced Bioavailability
61/435,997	US		1/25/2011		S-Adenosylmethionine Formulations With Enhanced Bioavailability
12/845,555	US		7/28/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
13/811,772	US		2/21/2013		S-Adenosylmethionine Formulations With Enhanced Bioavailability
PCT/IB2010/01877	WO		7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
PCT/CA2011/050462	WO		7/27/2011		S-Adenosylmethionine Formulations With Enhanced Bioavailability
2010277301	AU	2010277301	7/29/2010	5/8/2014	S-Adenosylmethionine Formulations With Enhanced Bioavailability
2,769,582	CA	2,769,582	7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
201080044205.X	CN		7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
10803973.6	EP	2512490	7/29/2010	1/27/2016	S-Adenosylmethionine Formulations With Enhanced Bioavailability
12110807.8	HK	1170155	7/29/2010	7/15/2016	S-Adenosylmethionine Formulations With Enhanced Bioavailability
1573/DELNP/2012	IN		7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
2012-522272	JP		7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
10-2012-7005274	KR		7/29/2010		S-Adenosylmethionine Formulations With Enhanced Bioavailability
61/612,105	US		3/16/2012		Diagnostic Methods For The Treatment Of Depression
61/715,138	US		10/17/2012		Compositions Comprising Antioxidants And S-Adenosylmethionine

Application No.	Country	Patent No.	Filing Date	Issue Date	Title
14/247,061	US	8975238	4/7/2014	3/10/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
14/628,623	US	9925208	2/23/2015	3/27/2018	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
15/932,359	US		2/16/2018		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
14/436,418	US	9801896	4/16/2015	10/31/2017	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
PCT/CA2013/000876	WO		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2013332209	AU	2013332209	10/16/2013	6/29/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2,888,302	CA	2,888,302	10/16/2013	5/31/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	CH	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
201380054342.5	CN	ZL201380054342.5	10/16/2013	9/7/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
201610230503.7	CN		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	DE	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	DK	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	EP	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
15162054.9	EP		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	ES	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	FI	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	FR	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	GB	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
15100380.1	HK	1199836B	10/16/2013	6/24/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester

Application No.	Country	Patent No.	Filing Date	Issue Date	Title
16105924.2	HK		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	IE	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
238181	IL	238181	10/16/2013	5/1/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
243585	IL		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
4151/DELNP/2015	IN		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	IT	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2015-537091	JP	5877935	10/16/2013	2/5/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2015-238622	JP	6280535	10/16/2013	1/26/2018	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
10-2015-7012788	KR	1748053	10/16/2013	6/9/2017	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
10-2016-7020590	KR		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
J/002364	MO	J/002364	10/16/2013	1/11/2017	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	NL	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	NO	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2015118235	RU	2586300	10/16/2013	5/16/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
2016117290	RU		10/16/2013		Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
13834351.2	SE	2753336	10/16/2013	5/6/2015	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
11201503048T	SG	11201503048T	10/16/2013	2/29/2016	Compositions Comprising S-Adenosylmethionine And A Gallic Acid Ester
61/765,562	US		2/15/2013		Diagnostic Methods For The Treatment Of Depression
61/931,098	US		1/24/2014		Diagnostic Methods For The Treatment Of Depression
62/106,880	US		1/23/2015		Diagnostic Methods For The Treatment Of Depression

Application No.	Country	Patent No.	Filing Date	Issue Date	Title
62/281,858	US		1/22/2016		Diagnostic Methods For The Treatment Of Depression
62/449,467	US		1/23/2017		Diagnostic Methods For The Treatment Of Depression
61/979,288	US		4/14/2014		Novel Ademetonine Formulations
15/304,164	US		10/14/2016		Novel Ademetonine Formulations
PCT/IB2015/001143	WO		4/13/2015		Novel Ademetonine Formulations
201580031933.X	CN		4/13/2015		Novel Ademetonine Formulations
15779654.1	EP		4/13/2015		Novel Ademetonine Formulations
17111288.9	HK		4/13/2015		Novel Ademetonine Formulations
61/979,242	US		4/14/2014		Stabilized Ademetonine Formulations
62/145,704	US		4/10/2015		Stabilized Ademetonine Formulations